DHR$219.4
$218.3
Chart
Performance
Key Stats
AI DHR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyDanaher Corporation presents a mixed but generally positive investment profile. Fundamentally strong with solid profitability and manageable debt, supported by positive long-term thematic trends in life sciences and diagnostics. However, current technicals indicate some short-term overbought conditions, suggesting potential for near-term volatility.
Thematic
Danaher is positioned to benefit from long-term secular growth trends in biotechnology, life sciences, and diagnostics, driven by an aging global population, increasing healthcare spending, and advancements in scientific research and medical technology.
Fundamental
Danaher demonstrates robust financial health with strong profitability, efficient operations, and a solid balance sheet. Revenue and earnings have shown resilience, with a commitment to returning capital to shareholders through dividends.
Technical
The stock is showing signs of recovery and is trading above key long-term moving averages. However, short-term momentum indicators suggest potential consolidation or a mild pullback after recent gains.
| Factor | Score |
|---|---|
| Biotechnology Advancements | 90 |
| Healthcare Demand | 85 |
| Research & Development Investment | 80 |
| Emerging Markets Expansion | 75 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 80 |
| Growth | 45 |
| Balance Sheet Health | 85 |
| Cash Flow | 85 |
| Dividend Yield | 50 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume | 65 |
| Support & Resistance | 70 |
| Short-term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent EPS Beat
The company has exceeded earnings per share (EPS) estimates for the last four consecutive quarters, indicating strong operational execution and profitability management.
Attractive P/E Ratio
The trailing Price-to-Earnings (P/E) ratio of 43.06 is competitive within its industry, suggesting the stock may be reasonably valued given its earnings potential.
Bearish Points (7)
Negative 6-Month and Year-to-Date Returns
The stock has experienced a decline of -18.81% over the last 6 months and -11.47% year-to-date, indicating recent underperformance.
High Quarterly P/E Ratio
Some quarterly P/E ratios, such as 254.9 for Q2 2025 and 153.6 for Q1 2025, are significantly elevated, potentially indicating overvaluation in the short term.
Calendar
June 2025
27
Ex-Dividend Date
July 2025
25
Next Dividend Date
October 2025
21
Next Earnings Date
H: $1.81
A: $1.73
L: $1.69
H: 6.04B
A: 5.99B
L: 5.91B
Profile
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Seasonals
Price Target
248.46 USD
The 39 analysts offering 1 year price forecasts for DHR have a max estimate of 310.00 and a min estimate of 205.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct and broad competitor across life sciences, diagnostics, and analytical instruments, offering similar product portfolios and serving overlapping customer bases.
Weight: 95
Major competitor in analytical instruments, life science tools, and diagnostics, with significant market overlap and product lines in mass spectrometry, chromatography, and genomics.
Weight: 93
Global leader in diagnostics and pharmaceuticals, directly competing with Danaher's diagnostics segment in areas like immunoassay and clinical chemistry.
Weight: 92
Significant competitor in in-vitro diagnostics (e.g., immunoassay, molecular diagnostics), medical devices, and nutrition, serving similar healthcare markets.